Bessemer Group’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Bessemer Group’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-230	Closed	–	–	2094
2022 Q1	$0	Hold	230	–	–	﹤0.01%	2010
2021 Q4	$0	Hold	230	–	–	﹤0.01%	2015
2021 Q3	$1K	Hold	230	–	–	﹤0.01%	1640
2021 Q2	$1K	Hold	230	–	–	﹤0.01%	1563
2021 Q1	$1K	Buy	+230	New	+$4.35K	﹤0.01%	1483
2020 Q3	–	Sell	-18,100	Closed	-$766K	–	1761
2020 Q2	$766K	Buy	+18,100	New	+$586K	﹤0.01%	876

Bessemer Group's ODT Position: Q2 2022 in Review

Bessemer Group sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2022, closing a stake of 230 shares.

Bessemer Group first reported a position in ODT in Q2 2020 and held it in 6 quarters. The position peaked at $766K in Q2 2020. 0 funds tracked by Wall St. Rank hold ODT as of Q2 2022.

Bessemer Group reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bessemer Group sold 230 Odonate Therapeutics, Inc. Common Stock shares in Q2 2022.
Bessemer Group first reported a position in Odonate Therapeutics, Inc. Common Stock in Q2 2020 and held it in 6 quarters.
Bessemer Group's Odonate Therapeutics, Inc. Common Stock position peaked at $766K in Q2 2020.
0 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.